MIR939

Summary

MIR939 (microRNA 939, HGNC:33682) is a microRNA gene on chromosome 8q24.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100126351 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33682
Approved symbol	MIR939
Name	microRNA 939
Location	8q24.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-939
Ensembl gene	ENSG00000284310
Ensembl biotype	miRNA
Entrez	100126351
RNAcentral	URS000069D7BD — miRNA, 82 nt, 8 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000401314

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000401314 — 1 exons

Exon	Start	End
ENSE00001546658	144394149	144394230

Expression profiles

Bgee: expression breadth broad, 52 present calls, max score 75.34.

Top tissues by expression

52 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium	UBERON:0001295	75.34	gold quality
skeletal muscle tissue	UBERON:0001134	75.13	gold quality
bone marrow	UBERON:0002371	73.69	gold quality
thoracic mammary gland	UBERON:0005200	73.36	gold quality
heart left ventricle	UBERON:0002084	68.26	gold quality
blood	UBERON:0000178	67.45	gold quality
muscle of leg	UBERON:0001383	66.92	gold quality
adrenal tissue	UBERON:0018303	66.91	gold quality
gastrocnemius	UBERON:0001388	66.15	gold quality
nucleus accumbens	UBERON:0001882	66.06	gold quality
right lobe of liver	UBERON:0001114	65.64	gold quality
amygdala	UBERON:0001876	65.09	gold quality
fallopian tube	UBERON:0003889	65.05	gold quality
myometrium	UBERON:0001296	64.98	gold quality
body of pancreas	UBERON:0001150	64.04	gold quality
right atrium auricular region	UBERON:0006631	63.24	gold quality
left ovary	UBERON:0002119	63.10	gold quality
hypothalamus	UBERON:0001898	62.83	gold quality
minor salivary gland	UBERON:0001830	62.36	gold quality
body of stomach	UBERON:0001161	61.12	gold quality
transverse colon	UBERON:0001157	59.69	gold quality
multicellular organism	UBERON:0000468	58.98	gold quality
small intestine Peyer’s patch	UBERON:0003454	58.46	gold quality
skin of abdomen	UBERON:0001416	57.74	gold quality
subcutaneous adipose tissue	UBERON:0002190	57.63	gold quality
skin of leg	UBERON:0001511	57.48	gold quality
ovary	UBERON:0000992	57.31	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	57.22	gold quality
tibial nerve	UBERON:0001323	56.46	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	56.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 23)

• A micro RNA expressed in a plasmid vector inhibits H1N1 influenza virus replication in cultured MDCK cells. (PMID:21141477)
• These findings suggest dual regulation of iNOS gene expression where cytokines induce iNOS transcription and also increase miR-939, leading to translational inhibition in a check-and-balance system. (PMID:22451906)
• miR-939 functioned as a potential tumor promoter by regulating the Wnt/beta-catenin signal pathway through direct suppression of APC2 expression. (PMID:25960217)
• we have identified that miR-939 targets CD2AP promoter sequences and suppresses its gene expression. These findings suggest that miRNAs may mediate podocyte injury via reducing the expression of the SD proteins, such as CD2AP (PMID:26895305)
• Collectively, these data suggest that miR-939 may regulate multiple proinflammatory genes and that downregulation of miR-939 in complex regional pain syndrome patients may increase expression of these genes, resulting in amplification of the inflammatory pain signal transduction cascade. (PMID:27498764)
• Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. (PMID:27693459)
• Taken together, the authors propose that the miR-939-Jmjd3 axis perturbs the accessibility of hepatitis B virus enhancer II/core promoter (En II) promoter to essential nuclear factors (C/EBPalpha and SWI/SNF complex) therefore leading to compromised viral RNA synthesis and hence restricted viral multiplication. (PMID:27779233)
• study revealed that the expression of circulating miR-939 was down-regulated in CAD patients with sufficient CCC. MiR-939 abolished vascular integrity and repressed angiogenesis through directly targeting gamma-catenin. It provided a potential biomarker and a therapeutic target for CAD (PMID:28115160)
• here for the first time, hsa-miR-939 is introduced as a novel key regulator of NGFR expression and its involvement in cell death/survival processes is suggested. (PMID:28229962)
• Study demonstrated that miR-939 expression is regulated by lncRNA-HEIH promoting colorectal tumorigenesis through transcriptional repression of Bcl-xL. (PMID:29081216)
• Our study shows the potential function of mir-939 through regulating LRSAM1 in Hirschsprung’s disease (PMID:29253842)
• Exosomes derived from patients with myocardial ischemia promote angiogenesis via the miR-939-iNOS-nitric oxide pathway. (PMID:29721064)
• RNA, circular (Circ-SATB2) regulates cell proliferation, differentiation and migration of vascular smooth muscle cells (VSMCs) through miR-939/stromal interaction molecule 1 protein (STIM1). (PMID:30241943)
• the present study demonstrated that miR-939 was able to regulate NSCLC cell proliferation and invasion. Additionally, miR-939 negatively regulated TIMP2 by binding to its 3’UTR. (PMID:30272338)
• lncRNA RP5-916L7.2 was up regulated in tumor tissue and positively correlated with tumor stage, and promoted cells proliferation while inhibited cells apoptosis by targeting miR-328-5p and miR-939-5p in tongue squamous cell carcinoma. (PMID:30825424)
• miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma. (PMID:32299901)
• Long noncoding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11. (PMID:32705287)
• Differentially expressed lnc-NOS2P3-miR-939-5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNFalpha pathway. (PMID:32844595)
• LncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production. (PMID:33368266)
• Overexpression of microRNA-939-5p Contributes to Cell Proliferation and Associates Poor Prognosis in Glioma. (PMID:33786745)
• Circular RNA circ_0058123 Targets the miR-939-5p/RAC1 Pathway to Promote the Development of Colorectal Cancer. (PMID:37642813)
• miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review. (PMID:38679648)
• MicroRNA-939 amplifies Staphylococcus aureus-induced matrix metalloproteinase expression in atopic dermatitis. (PMID:38903509)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.